The Board of Aurobindo Pharma at its meeting held on 12 November 2018 has transacted the following -
The company's subsidiary - Aurobindo Pharma USA Inc., USA, has entered into an agreement to acquire a product under development and related assets from 'Advent Pharmaceuticals, Australia, through AuroScience, Melbourne, a 100% subsidiary of Aurobindo Pharma USA Inc., USA. The transaction is expected to close in January 2019. The cost of acquisition is USD 12.5 million.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
